UK-based pharmaceutical firm GlaxoSmithKline (GSK) and US-based healthcare firm Innoviva have reported positive headline results from a non-inferiority lung function study of relvar ellipta in patients with well-controlled asthma.

Relvar ellipta is a once-daily dual combination of inhaled corticosteroid fluticasone furoate and beta-2 agonist vilanterol in a single inhaler, the Ellipta.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The results showed that patients with well-controlled asthma were able to switch to the once-daily relvar ellipta 100/25 from the twice-daily seretide accuhaler 250/50 without any affect on their lung function.

Seretide accuhaler is a twice-daily dual combination of fluticasone propionate / salmeterol in the Accuhaler inhaler.

The randomised, double-blind, double-dummy European Medicines Agency (EMA) approved study was conducted at multiple centres in 12 countries.

“The patients administered with relvar ellipta were found to maintain a better lung function when compared to patients who were given seretide accuhaler.”

The study’s primary objective was to establish the non-inferiority of relvar ellipta 100/25 once-daily, when compared to seretide accuhaler 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent bronchial asthma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study endpoint was the change from baseline during clinic visit evening FEV1 (pre-brochodilator and pre-dose) at the end of the 24-week treatment period.

The patients administered with relvar ellipta were found to maintain a better lung function when compared to patients who were given seretide accuhaler.

The study also included a third treatment arm with fluticasone propionate (FP), inhaled corticosteroid monotherapy to identify the lung function difference between treatments.

The serious adverse events (SAEs) and adverse events (AEs) were found to be consistent with the safety profile of relvar ellipta that was determined through previous studies.

Relvar ellipta is currently indicated in Europe for the regular treatment of patients aged 12 and above with asthma.